2020
LITT for Metastatic In-Field Recurrence
Sujijantarat N, Danish S, Chiang V. LITT for Metastatic In-Field Recurrence. 2020, 51-64. DOI: 10.1007/978-3-030-48047-9_5.Peer-Reviewed Original ResearchLaser interstitial thermal therapyNeurological outcomeRadiation necrosisProgression-free survival ratesInitiation of steroidsMulticenter prospective seriesSystemic therapy optionsAdverse neurological outcomesLarge prospective studiesSuitable surgical candidatesBlood-brain barrierInterstitial thermal therapyContrast-enhancing volumeBrain metastasesSurgical candidatesProspective seriesClinical outcomesImaging changesSymptom managementCancer survivorsProspective studyTherapeutic managementTherapy optionsFLAIR volumeInvasive approach
2018
Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis.
Ahluwalia M, Barnett GH, Deng D, Tatter SB, Laxton AW, Mohammadi AM, Leuthardt E, Chamoun R, Judy K, Asher A, Essig M, Dietrich J, Chiang VL. Laser ablation after stereotactic radiosurgery: a multicenter prospective study in patients with metastatic brain tumors and radiation necrosis. Journal Of Neurosurgery 2018, 130: 804-811. PMID: 29726782, DOI: 10.3171/2017.11.jns171273.Peer-Reviewed Original ResearchMeSH KeywordsAblation TechniquesAdultAgedBrain NeoplasmsFemaleHumansKarnofsky Performance StatusLaser TherapyMagnetic Resonance ImagingMaleMiddle AgedNecrosisNeoplasm Recurrence, LocalPostoperative ComplicationsProgression-Free SurvivalProspective StudiesQuality of LifeRadiation InjuriesRadiosurgeryTreatment OutcomeConceptsProgression-free survivalQuality of lifeKarnofsky Performance ScaleMulticenter prospective studyKPS scoreRecurrent tumorsStereotactic radiosurgeryOverall survivalProspective studyRadiation necrosisNeuro-Oncology Brain Metastases criteriaLocal progression-free survivalMedian KPS scoreSteroid sparing effectMetastatic brain tumorsLength of stayPercent of subjectsDuration of survivalOverall event rateSignificant differencesMajority of casesMetastasis (TNM) criteriaOS advantageProgression patientsBrain metastases
2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer
Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal Of Neuro-Oncology 2013, 112: 467-472. PMID: 23462853, DOI: 10.1007/s11060-013-1083-9.Peer-Reviewed Original ResearchConceptsNumber of BMBrain metastasesGraded Prognostic AssessmentPrimary diagnosisPrognostic factorsTumor subtypesMedian survivalBreast cancerDiagnosis-Specific Graded Prognostic AssessmentDevelopment of BMMulti-institutional retrospective databaseImportant prognostic factorIndependent prognostic factorBreast cancer patientsER/PRBreast cancer subtypesBreast-GPAProspective studyCancer patientsLuminal ALuminal BRetrospective databaseHER2 subtypeBrain MRIPrognostic assessment